Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Trial Profile

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Mar 2018 New trial record
    • 10 Feb 2018 Results assessing genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells, presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top